BioScrip, Inc. (NASDAQ:BIOS) has 1 year Price Target of $2.54

TG Therapeutics, Inc. (NASDAQ:TGTX) announced positive topline results from its Phase 3 GENUINE clinical trial of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia (CLL). This rating was issued on 11/08/16.

BioScrip Inc (NASDAQ:BIOS) had its target price raised by Barrington Research from $1.50 to $2.25 in a research note issued to investors on Monday. Analyst's mean target price for BIOS is $2.54 while analysts mean recommendation is 1.70. They now have a Dollars 3 price target on the stock. "Continued execution of the CORE program positions BioScrip for the sustainable growth of our higher-margin core business and ongoing improvement of our operating processes, driving our future financial performance and creating value for our shareholders", commented Daniel E. Greenleaf, President and CEO. (NASDAQ:BIOS) to Neutral with no specific Price Target on 8/11/15. They now have a Dollars 6 price target on the stock. FMR LLC now owns 3,529,795 shares of the company's stock valued at $3,671,000 after buying an additional 3,431,447 shares in the last quarter. (NASDAQ:BIOS) may hit a high of $4.5.

6 analysts projected Price Targets for BioScrip, Inc.

Analysts estimated $-0.08/share for the previous Quarter, where BioScrip, Inc. Zacks Investment Research cut BioScrip from a "hold" rating to a "sell" rating in a report on Monday, November 14th.

The Stock had a 1.5 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.5 and 1.5 respectively. For the full-year 2016, the Company reported revenue from continuing operations of $935.6 million, net loss from continuing operations of ($34.4) million and diluted EPS of ($0.46) loss per share. The analyst projections are -$0.1 in EPS on $234.07 million in revenues. Thus the company showed an Earnings Surprise of -120 Percent.

The Stock now has the market capitalization of $211.95 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 13.69% and monthly volatility of 8.52% respectively. The stock traded with the volume of 12.93 Million shares in the last trading session. BioScrip has a 52 week low of $0.98 and a 52 week high of $3.43.

BioScrip, Inc. has 1 year price target of $2.54. Jefferies Group LLC now has a buy rating on the stock. The Moving Average SMA50 is 28.06% while SMA200 is -16.18%. Return on Equity (ROE) stands at 104.9% and Return on Investment (ROI) of -78.9 percent. The stock now shows its YTD (Year to Date) performance of 76.92 percent while its Weekly performance value is 16.46%.

Consolidated Adjusted EBITDA was $9.5 million for the fourth quarter 2016, as compared to the $9.0 million consolidated Adjusted EBITDA in the prior year fourth quarter.

BioScrip, Inc is engaged in providing infusion solutions. When we divide the current volume by the three-month average volume, we get a relative volume of 2.94.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Given that liquidity is king in short-term, BIOS is a stock with 93.37 million shares outstanding that normally trades 0% of its float.

  • Zachary Reyes